score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline			Copy Number	CDK4	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				CDK4 Amplification	1.0	KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Putatively Actionable	Preclinical			Copy Number	MDM2	Amplification				0.0	0.0		Putatively Actionable	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	https://doi.org/10.1111/j.1349-7006.2010.01821.x													0				MDM2 Amplification	0.0	KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.317						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (32%)		KIRP-SX-A7SM		
Biologically Relevant				Copy Number	ERBB3	Amplification				0.0	0.0																					0				ERBB3 Amplification		KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Biologically Relevant				Copy Number	ETV6	Amplification				0.0	0.0																					0				ETV6 Amplification		KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Biologically Relevant				Copy Number	PTPN11	Amplification				0.0	0.0																					0				PTPN11 Amplification		KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Biologically Relevant				Copy Number	KRAS	Amplification				0.0	0.0																					0				KRAS Amplification		KIRP-SX-A7SM	TCGA-SX-A7SM-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), nan																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), nan		KIRP-SX-A7SM		
Biologically Relevant				Mutational Signature	COSMIC Signature 8	version 2	0.208																									0				COSMIC Signature (version 2) 8 (21%)		KIRP-SX-A7SM		
